| Literature DB >> 30545134 |
Juan Mielgo-Ayuso1, Julio Calleja-González2, Aritz Urdampilleta3, Patxi León-Guereño4, Alfredo Córdova5, Alberto Caballero-García6, Diego Fernandez-Lázaro7.
Abstract
INTRODUCTION: Deficient levels of 25-hydroxyvitamin D (25(OH)D) (<30 ng/mL) may compromise health and athletic performance. Supplementation with oral vitamin D can favor the state of iron metabolism, and testosterone and cortisol as an indicator of muscle recovery of the athlete with a deficiency. The main aim of this study was to evaluate the influence of eight weeks of supplementation with 3000 IU/day of vitamin D on the hematological and iron metabolism profile, as well as on the analytical values of testosterone and cortisol on elite male traditional rowers. The secondary aim was to examine if serum 25(OH)D is a predictor of testosterone and cortisol levels.Entities:
Keywords: cortisol; hematocrit; hemoglobin; recovery; strength-endurance; testosterone; vitamin D
Mesh:
Substances:
Year: 2018 PMID: 30545134 PMCID: PMC6315465 DOI: 10.3390/nu10121968
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Serum 25(OH)D in the control group (CG) and vitamin D3 treatment group (VD3G) at baseline (T1) and after 8 weeks (T2). P: group-by-time interaction (p < 0.05 all such occurrences). Two-factor repeated-measures ANOVA. * Significantly different between phases (T1 vs. T2). p < 0.05. & Significantly different between groups (CG vs. VD3G). p < 0.05.
Hematological parameters in control group (CG) and vitamin D3 treatment group (VD3G) at baseline (T1) and after 8 weeks (T2).
| T1 | T2 | P | η2p | |
|---|---|---|---|---|
|
| ||||
| CG | 81.33 ± 17.75 | 72.78 ± 11.26 | 0.466 | 0.034 |
| VD3G | 76.67 ± 23.7 | 77.11 ± 26.51 | ||
|
| ||||
| CG | 74.67 ± 42.27 | 84.44 ± 28.05 | 0.403 | 0.044 |
| VD3G | 81.44 ± 38.26 | 84.33 ± 40.82 | ||
|
| ||||
| CG | 15.54 ± 0.88 | 15.09 ± 0.82 * | 0.009 | 0.354 |
| VD3G | 14.76 ± 0.77 | 14.76 ± 0.58 | ||
|
| ||||
| CG | 46.04 ± 2.55 | 45.29 ± 2.12 | 0.019 | 0.300 |
| VD3G | 44.59 ± 2.27 | 45.07 ± 1.74 | ||
|
| ||||
| CG | 252.89 ± 46.51 | 253.22 ± 38.86 | 0.007 | 0.374 |
| VD3G | 254.22 ± 20.69 | 270.44 ± 20.08 * | ||
Data are expressed as mean ± standard deviation. P: group-by-time interaction (p < 0.05, all such occurrences). Two-factor repeated-measures ANOVA. * Significantly different between phases (T1 vs. T2), p < 0.05.
Hormonal parameters in the control group (CG) and vitamin D3 treatment group (VD3G) at baseline (T1) and after 8 weeks (T2).
| T1 | T2 | P | η2p | |
|---|---|---|---|---|
|
| ||||
| CG | 20.44 ± 4.71 | 17.81 ± 2.16 * | 0.561 | 0.022 |
| VD3G | 21.73 ± 4.61 | 18.18 ± 4.25 * | ||
|
| ||||
| CG | 5.06 ± 1.41 | 4.37 ± 0.96 * | 0.852 | 0.002 |
| VD3G | 5.37 ± 1.5 | 4.73 ± 1.28 * | ||
|
| ||||
| CG | 25.22 ± 6.18 | 24.49 ± 3.71 | 0.613 | 0.016 |
| VD3G | 25.66 ± 7.98 | 27.65 ± 9.53 | ||
Data are expressed as mean ± standard deviation. P: group-by-time interaction (p < 0.05, all such occurrences). Two-factor repeated-measures ANOVA. * Significantly different between phases (T1 vs. T2), p < 0.05.
State of serum 25(OH)D in the control group (CG; n = 9) and vitamin D3 treatment group (ITG; n = 9) at baseline (T1) and after 8 weeks (T2).
| T1 | T2 | P | |||
|---|---|---|---|---|---|
|
|
|
|
| <0.001 | |
|
| 18 (100%) | 0 (0%) | 18 (100%) | 0 (0%) | |
|
| 18 (100%) | 0 (0%) | 9 (50%) | 9 (50%) | |
Data expressed in frequency (%). Non-optimal level of 25(OH)D for athletic performance enhancement: <50 ng/mL; optimal level of 25(OH)D for athletic performance enhancement: ≥50 ng/mL [3]. P: McNemar test.
Energy and micronutrients intake in control group (CG) and vitamin D3 group (VD3G) during 8 weeks of study.
| CG ( | VD3G ( | P | |
|---|---|---|---|
| Energy (Kcal) | 2818.9 ± 748.5 | 2942.4 ± 543.9 | 0.668 |
| Proteins (g) | 144.1 ± 37.1 | 128.3 ± 44.6 | 0.391 |
| Fats (g) | 138.3 ± 43.6 | 142.0 ± 43.9 | 0.848 |
| Carbohydrates (g) | 249.7 ± 118.0 | 286.1 ± 64.0 | 0.384 |
| Ca (mg) | 981.9 ± 628.7 | 806.9 ± 344.4 | 0.433 |
| Mg (mg) | 377.4 ± 139.8 | 391.7 ± 120.4 | 0.804 |
| P (mg) | 1704.8 ± 595.0 | 1734.1 ± 416.9 | 0.987 |
| Fe (mg) | 16.3 ± 6.2 | 16.7 ± 6.0 | 0.880 |
| Zn (mg) | 13.0 ± 3.9 | 13.7 ± 2.5 | 0.591 |
| Vitamin A (µg) | 959.2 ± 504.5 | 714.6 ± 374.2 | 0.219 |
| Vitamin D (µg) | 16.9 ± 6.3 | 15.3 ± 5.3 | 0.415 |
| Vitamin E (mg) | 20.8 ± 12.1 | 16.8 ± 7.4 | 0.369 |
| Thiamin (mg) | 1.4 ± 0.6 | 1.8 ± 0.6 | 0.148 |
| Riboflavin (mg) | 2.1 ± 0.75 | 2.0 ± 0.6 | 0.832 |
| Niacin (mg) | 34.3 ± 10.9 | 35.4 ± 10.5 | 0.812 |
| Vitamin B6 (mg) | 3.23 ± 0.94 | 2.9 ± 1.0 | 0.477 |
| Folic Acid (mg) | 428.2 ± 112.3 | 339.2 ± 108.4 | 0.081 |
| Vitamin B12 (mg) | 8.6 ± 3.7 | 8.1 ± 3.4 | 0.719 |
| Vitamin C (mg) | 179.7 ± 48.6 | 138.2 ± 88.4 | 0.206 |
Data are expressed as mean ± standard deviation. P: Significantly different between groups by independent t-test.
Daily number of portions of different food groups in the control group (CG) and vitamin D3 group (VD3G) during 8 weeks of study.
| CG ( | VD3G ( | P | |
|---|---|---|---|
| Cereals/grains (150 g cooked weight) | 4.26 ± 0.35 | 4.31 ± 0.42 | 0.7004 |
| Milk and dairy products (200 ml) | 2.81 ± 0.35 | 2.76 ± 0.32 | 0.6575 |
| Fruits (120–150 g) | 2.47 ± 0.82 | 2.51 ± 0.72 | 0.8773 |
| Vegetables (120–150 g) | 2.67 ± 0.65 | 2.47 ± 0.74 | 0.3950 |
| Oil and fats (12 g) | 2.28 ± 0.32 | 2.31 ± 0.41 | 0.8081 |
| Legumes (150 g cooked weight) | 0.51 ± 0.23 | 0.50 ± 0.21 | 0.8924 |
| Dry fruits (20–30 g) | 0.42 ± 0.18 | 0.38 ± 0.21 | 0.5436 |
| Fish (120–150 g) | 1.89 ± 0.33 | 1.95 ± 0.41 | 0.6317 |
| Meat and meat products (120–150 g) | 1.09 ± 0.45 | 1.00 ± 0.64 | 0.6286 |
| Eggs (units) | 0.50 ± 0.01 | 0.50 ± 0.01 | 1.000 |
| Sugar and sweets (30–50 g) | 0.87 ± 0.25 | 0.77 ± 0.18 | 0.1774 |
| Nonalcoholic beverages (200 ml) | 0.27 ± 0.18 | 0.30 ± 0.15 | 0.5905 |
Data are expressed as mean ± standard deviation. P: Significantly different between groups by independent t-test.
Body composition in the control group (CG) and vitamin D3 group (VD3G) at baseline (T1) and after 8 weeks (T2).
| T1 | T2 | P | η2p | |
|---|---|---|---|---|
|
| ||||
| GC | 77.0 ± 7.6 | 76.3 ± 7.3 * | 0.817 | 0.005 |
| GVD3 | 76.2 ± 10.1 | 76.3 ± 11.0 * | ||
|
| ||||
| GC | 23.46 ± 1.63 | 23.25 ± 1.58 * | 0.777 | 0.008 |
| GVD3 | 23.50 ± 1.35 | 23.51 ± 1.59 | ||
|
| ||||
| GC | 47.15 ± 11.35 | 44.10 ± 8.84 * | 0.253 | 0.117 |
| GVD3 | 49.59 ± 18.58 | 41.83 ± 11.77 | ||
|
| ||||
| GC | 13.00 ± 1.74 | 12.53 ± 1.35 * | 0.253 | 0.117 |
| GVD3 | 13.37 ± 2.84 | 12.18 ± 1.80 * | ||
|
| ||||
| GC | 10.02 ± 1.82 | 9.56 ± 1.37 * | 0.507 | 0.041 |
| GVD3 | 10.25 ± 2.63 | 9.38 ± 2.29 * | ||
|
| ||||
| GC | 67.00 ± 6.54 | 70.85 ± 10.94 * | 0.348 | 0.080 |
| GVD3 | 65.94 ± 8.61 | 66.57 ± 9.19 * | ||
Data are expressed as mean ± standard deviation. P: group-by-time interaction (p < 0.05. all such occurrences). Two-factor repeated-measures ANOVA. * Significantly different between phases (T1 vs. T2), p < 0.05.
Regression multivariate analysis with catabolic–anabolic hormones as the dependent variable and 25(OH) D as predictor.
| Unstandardized Coefficients | Standardized Coefficients | t | P | ||
|---|---|---|---|---|---|
| B | Std. Error | Beta | |||
|
| |||||
| (Constant) | 24.796 | 2.089 | 11.82 | <0.000 | |
| 25(OH)D | −0.147 | 0.057 | −0.407 | −2.597 | 0.014 |
|
| |||||
| (Constant) | 6.425 | 0.649 | 9.902 | <0.000 | |
| 25(OH)D | 0.44 | 0.018 | 0.394 | 2.501 | 0.017 |
|
| |||||
| (Constant) | 26.755 | 3.772 | 7.092 | <0.000 | |
| 25(OH)D | −0.029 | 0.102 | −0.48 | −0.279 | 0.782 |
p < 0.05 indicates significative association between predictor (25(OH) D) and dependent variables (catabolic–anabolic hormones).